NovaGenesis Peptide Research
← Peptide Library
SIGNALLING RESEARCHPT1

PT-141

A melanocortin receptor agonist studied for central signalling pathways and neurogenic response research.

Half-Life
Moderate
Onset
Fast
Symbol
PT1
Category
Signalling

⏱ Half-Life

Moderate duration profile

PT-141 demonstrates a moderate half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Fast measurable response

Onset is observed as fast — a property that influences how researchers structure comparative studies versus other compounds in the signalling research category.

🧠 Key Notes

What makes it distinct

  • 01Acts on central melanocortin receptors in research models
  • 02Studied for rapid onset characteristics
  • 03Distinct receptor profile vs cognitive peptides

🧬 Mechanism of Action

How it works

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that selectively activates the MC4R melanocortin receptor in the central nervous system, with secondary activity at MC3R. Unlike vasoactive compounds, it acts on neural pathways in the hypothalamus to trigger arousal and neurogenic responses centrally rather than through vascular dilation. This central mechanism makes it effective regardless of vascular health, distinguishing it from PDE5-inhibitor-class compounds. Its activity is independent of the dopaminergic or sex-hormone pathways that other libido-related research compounds rely on.

✨ Documented Benefits

What the research shows it supports

B01Triggers central arousal and libido response via MC4R activation in research models.
B02Acts independently of vascular pathways, effective in vascular-impaired research populations.
B03Rapid onset (often within 1–2 hours) following subcutaneous administration.
B04FDA-approved as bremelanotide for hypoactive sexual desire disorder, providing robust pharmacology data.
B05Non-hormonal mechanism — does not interact with testosterone or oestrogen pathways.

🔍 Research Insights

What the literature shows

INSIGHT 01

Selectively activates MC4R receptors in the central nervous system — distinct from MT2's broader pan-melanocortin profile.

INSIGHT 02

Acts on neural pathways rather than vascular ones, making it a unique reference compound in neurogenic-response research.

INSIGHT 03

Approved as bremelanotide for clinical indications, providing a robust pharmacology dataset.

🧪 Typical Research Use Cases

Where it appears in study design

USE CASE 01

Central neurogenic-response and arousal research.

USE CASE 02

MC4R receptor selectivity studies.

USE CASE 03

Comparative melanocortin pathway research vs MT2.

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

  1. [01]

    Kingsberg, S. A. et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 134(5), 899–908.

    Obstetrics & Gynecology ↗
  2. [02]

    Pfaus, J. G., Sadiq, A., Spana, C., & Clayton, A. H. (2016). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 27(3), 281–289.

    CNS Spectrums ↗
  3. [03]

    Diamond, L. E. et al. (2004). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine, 3(4), 628–638.

    Journal of Sexual Medicine ↗
  4. [04]

    Molinoff, P. B. et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102.

    Annals of the NY Academy of Sciences ↗

Continue Exploring

Also explore: Semax, Selank, MOTS-c

Semax →Selank →MOTS-c →Half-Life Guide →Signalling Research →